Natalia Mouratidou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Natalia Mouratidou has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Johnny Ludvigsson
Division of Pediatrics, Department of Biomedical and Clinical Sciences Linköping University Linköping Sweden
2 shared publications Ola Olén
Division of Clinical Epidemiology; Department of Medicine Solna; Karolinska Institutet; Stockholm Sweden
2 shared publicationsPetter Malmborg
Division of Clinical Epidemiology; Department of Medicine Solna; Karolinska Institutet; Stockholm Sweden
2 shared publications- Ahad Khalilnezhad
The Gene Lay Institute of Immunology and Inflammation, Brigham and Women’s Hospital, Massachusetts General Hospital and Harvard Medical School, Boston, USA
1 shared publication - Amos Hong Pheng Loh
Department of Paediatric Surgery, KK Women's and Children's Hospital, Singapore
1 shared publication - Anastasia Resteu
Max‐Planck Institute for Marine Microbiology Bremen Germany
1 shared publication
Latest Publications
- Open Access
- 16 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 7 (78) , eadd3330
Notch-dependent cooperativity between myeloid lineages promotes Langerhans cell histiocytosis pathology
Langerhans cell histiocytosis (LCH) is a potentially fatal neoplasm characterized by the aberrant differentiation of mononuclear phagocytes, driven by mitogen-activated protein kinase (MAPK) pathway activation. LCH cells may trigger destructive pathology yet remain in a precarious state finely balanced between apoptosis and survival, supported by a unique inflammatory milieu. The interactions that maintain this state are not well known and may offer targets for intervention. Here, we used single-cell RNA-seq and protein analysis to dissect LCH lesions, assessing LCH cell heterogeneity and comparing LCH cells with normal mononuclear phagocytes within lesions. We found LCH discriminatory signatures pointing to senescence and escape from tumor immune surveillance. We also uncovered two major lineages of LCH with DC2- and DC3/monocyte-like phenotypes and validated them in multiple pathological tissue sites by high-content imaging. Receptor-ligand analyses and lineage tracing in vitro revealed Notch-dependent cooperativity between DC2 and DC3/monocyte lineages during expression of the pathognomonic LCH program. Our results present a convergent dual origin model of LCH with MAPK pathway activation occurring before fate commitment to DC2 and DC3/monocyte lineages and Notch-dependent cooperativity between lineages driving the development of LCH cells.
- 16 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 7 (78) , eadd3330
Open AccessNotch-dependent cooperativity between myeloid lineages promotes Langerhans cell histiocytosis pathology
Langerhans cell histiocytosis (LCH) is a potentially fatal neoplasm characterized by the aberrant differentiation of mononuclear phagocytes, driven by mitogen-activated protein kinase (MAPK) pathway activation. LCH cells may trigger destructive pathology yet remain in a precarious state finely balanced between apoptosis and survival, supported by a unique inflammatory milieu. The interactions that maintain this state are not well known and may offer targets for intervention. Here, we used single-cell RNA-seq and protein analysis to dissect LCH lesions, assessing LCH cell heterogeneity and comparing LCH cells with normal mononuclear phagocytes within lesions. We found LCH discriminatory signatures pointing to senescence and escape from tumor immune surveillance. We also uncovered two major lineages of LCH with DC2- and DC3/monocyte-like phenotypes and validated them in multiple pathological tissue sites by high-content imaging. Receptor-ligand analyses and lineage tracing in vitro revealed Notch-dependent cooperativity between DC2 and DC3/monocyte lineages during expression of the pathognomonic LCH program. Our results present a convergent dual origin model of LCH with MAPK pathway activation occurring before fate commitment to DC2 and DC3/monocyte lineages and Notch-dependent cooperativity between lineages driving the development of LCH cells.
- Open Access
- 1 April 2022
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 14, 591-600
Identification of Childhood-Onset Inflammatory Bowel Disease in Swedish Healthcare Registers: A Validation Study
Purpose: The Swedish National Patient Register (NPR) is often used in observational studies of childhood-onset inflammatory bowel disease (IBD) (< 18 years of age) and its subtypes, but the validity of previously used register-based algorithms for capturing childhood-onset IBD has never been examined. Methods: We identified a random sample of 233 individuals with at least two first ever diagnostic listings of IBD in the NPR between 2002 and 2014. We calculated the test characteristics for different register-based definitions of IBD and its subtypes using the Copenhagen criteria and the revised Porto criteria as gold standard, both based on medical chart review. We made assumptions of the occurrence of undiagnosed IBD in the general child population based on available literature. Results: Out of 233 individuals with at least two diagnostic listings of IBD, 216 had true IBD, resulting in a positive predictive value (PPV) = 93% (95% confidence interval (CI) 89– 96), sensitivity = 88% (95% CI 83– 92), specificity = 100% (95% CI 100– 100), and negative predictive value (NPV) = 100% (95% CI 100– 100). The PPV for the NPR-based definitions of IBD subtypes at time of first IBD diagnosis and at end of follow-up were 78% (95% CI 69– 86) and 88% (95% CI 80– 94), respectively, for Crohn’s disease and 74% (95% CI 63– 83) and 71% (95% CI 60– 80), respectively, for ulcerative colitis. Conclusion: The validity of register-based definitions of childhood-onset IBD in the Swedish NPR is high and can be used to identify patients in observational research.
- 1 April 2022
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 14, 591-600
Open AccessIdentification of Childhood-Onset Inflammatory Bowel Disease in Swedish Healthcare Registers: A Validation Study
Purpose: The Swedish National Patient Register (NPR) is often used in observational studies of childhood-onset inflammatory bowel disease (IBD) (< 18 years of age) and its subtypes, but the validity of previously used register-based algorithms for capturing childhood-onset IBD has never been examined. Methods: We identified a random sample of 233 individuals with at least two first ever diagnostic listings of IBD in the NPR between 2002 and 2014. We calculated the test characteristics for different register-based definitions of IBD and its subtypes using the Copenhagen criteria and the revised Porto criteria as gold standard, both based on medical chart review. We made assumptions of the occurrence of undiagnosed IBD in the general child population based on available literature. Results: Out of 233 individuals with at least two diagnostic listings of IBD, 216 had true IBD, resulting in a positive predictive value (PPV) = 93% (95% confidence interval (CI) 89– 96), sensitivity = 88% (95% CI 83– 92), specificity = 100% (95% CI 100– 100), and negative predictive value (NPV) = 100% (95% CI 100– 100). The PPV for the NPR-based definitions of IBD subtypes at time of first IBD diagnosis and at end of follow-up were 78% (95% CI 69– 86) and 88% (95% CI 80– 94), respectively, for Crohn’s disease and 74% (95% CI 63– 83) and 71% (95% CI 60– 80), respectively, for ulcerative colitis. Conclusion: The validity of register-based definitions of childhood-onset IBD in the Swedish NPR is high and can be used to identify patients in observational research.
- Open Access
- 1 August 2020
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 52 (3) , 560-561
Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings? Authors' reply
- 1 August 2020
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 52 (3) , 560-561
Open AccessLetter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings? Authors' reply
- Open Access
- 4 March 2020
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 51 (8) , 789-800
Adult height in patients with childhood‐onset inflammatory bowel disease: a nationwide population‐based cohort study
Summary: Background: Growth retardation is well described in childhood‐onset inflammatory bowel disease (IBD).Aims: To study if childhood‐onset IBD is associated with reduced final adult height.Methods: We identified 4201 individuals diagnosed with childhood‐onset IBD 1990‐2014 (Crohn's disease: n = 1640; ulcerative colitis: n = 2201 and IBD‐unclassified = 360) in the Swedish National Patient Register.Results: Patients with IBD attained a lower adult height compared to reference individuals (adjusted mean height difference [AMHD] −0.9 cm [95% CI −1.1 to −0.7]) and to their healthy siblings (AMHD −0.8 cm [−1.0 to −0.6]). Patients with Crohn’s disease (CD) were slightly shorter than patients with ulcerative colitis (UC; −1.3 cm vs −0.6 cm). Lower adult height was more often seen in patients with pre‐pubertal disease onset (AMHD −1.6 cm [−2.0 to −1.2]), and in patients with a more severe disease course (AMHD −1.9 cm, [−2.4 to −1.4]). Some 5.0% of CD and 4.3% of UC patients were classified as growth retarded vs 2.5% of matched reference individuals (OR 2.42 [95% CI 1.85‐3.17] and 1.74 [1.36‐2.22] respectively).Conclusion: Patients with childhood‐onset IBD on average attain a slightly lower adult height than their healthy peers. Adult height was more reduced in patients with pre‐pubertal onset of disease and in those with a more severe disease course.
- 4 March 2020
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 51 (8) , 789-800
Open AccessAdult height in patients with childhood‐onset inflammatory bowel disease: a nationwide population‐based cohort study
Summary: Background: Growth retardation is well described in childhood‐onset inflammatory bowel disease (IBD).Aims: To study if childhood‐onset IBD is associated with reduced final adult height.Methods: We identified 4201 individuals diagnosed with childhood‐onset IBD 1990‐2014 (Crohn's disease: n = 1640; ulcerative colitis: n = 2201 and IBD‐unclassified = 360) in the Swedish National Patient Register.Results: Patients with IBD attained a lower adult height compared to reference individuals (adjusted mean height difference [AMHD] −0.9 cm [95% CI −1.1 to −0.7]) and to their healthy siblings (AMHD −0.8 cm [−1.0 to −0.6]). Patients with Crohn’s disease (CD) were slightly shorter than patients with ulcerative colitis (UC; −1.3 cm vs −0.6 cm). Lower adult height was more often seen in patients with pre‐pubertal disease onset (AMHD −1.6 cm [−2.0 to −1.2]), and in patients with a more severe disease course (AMHD −1.9 cm, [−2.4 to −1.4]). Some 5.0% of CD and 4.3% of UC patients were classified as growth retarded vs 2.5% of matched reference individuals (OR 2.42 [95% CI 1.85‐3.17] and 1.74 [1.36‐2.22] respectively).Conclusion: Patients with childhood‐onset IBD on average attain a slightly lower adult height than their healthy peers. Adult height was more reduced in patients with pre‐pubertal onset of disease and in those with a more severe disease course.